Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
520 Results for "
monkey
" in MedChemExpress (MCE) Product Catalog:
Products (520)
520 Results for "monkey" in MCE Product Catalog:
Áreas de investigación:
Infection Neurological Disease Inflammation/Immunology Cancer
Eicosatetraynoic acid (ETYA) is a non-metabolizable analog of Arachidonic acid (HY-109590) and also an inhibitor of the lipoxygenase (LOX)/cyclooxygenase (COX) pathway (ID50 = 8 μM and 4 μM). Eicosatetraynoic acid acts as a suicide substrate to inhibit the production of inflammatory mediators such as leukotrienes and prostaglandins. Eicosatetraynoic acid acts directly on cell membranes and membrane proteins to exert a wide range of effects, including blocking potassium channels, increasing cell membrane fluidity, elevating intracellular calcium levels, inhibiting DNA synthesis in tumor cells, inducing differentiation of certain cells, and specifically inhibiting the assembly and replication of orthopoxviruses. Eicosatetraynoic acid alleviates acute lung injury induced by chemicals such as phosgene .
Referencia número: HY-128538
No. CAS: 1262873-06-2
Synonyms: ONO-9054
Target:
Áreas de investigación:
Sepetaprost (ONO-9054) is a dual agonist of the prostaglandin E3 receptor and prostaglandin F receptor. Sepetaprost reduces intraocular pressure in animal models. Sepetaprost is applicable for research on ocular hypertension and open-angle glaucoma .
Referencia número: HY-153492A
Pureza: 98.82%
Synonyms: AMG 890 sodium; ARC-LPA sodium
Target:
Áreas de investigación:
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .
Referencia número: HY-172661
No. CAS: 2661053-09-2
Áreas de investigación:
Kylo-0603 is an orally active thyroid hormone receptor β (THR-β) agonist with an EC50 of 31.07 nM against human targets, and it exhibits much higher selectivity for THR-β than for THR-α. Kylo-0603 enables hepatocyte-targeted delivery via GalNAc modification. Kylo-0603 reduces serum cholesterol and low-density lipoprotein cholesterol levels. Kylo-0603 alleviates hepatic steatosis, inflammatory responses, hepatocyte ballooning, and non-alcoholic steatohepatitis activity scores. Kylo-0603 inhibits the progression of hepatic fibrosis. Kylo-0603 can be used for research on metabolic dysfunction-associated steatohepatitis (MASH) .
Referencia número: HY-185492
No. CAS: 1799659-90-7
Áreas de investigación:
MC-cBu-Cit-seco-CBI dimer (Compound 10) is a conjugate of an ADC drug toxin molecule and a linker, which consists of a DNA alkylating agent connected to a reactive maleimide via a protease-cleavable peptidomimetic linker .
Referencia número: HY-N21530
No. CAS: 1295650-67-7
Referencia número: HY-P11786
No. CAS: 1020264-43-0
Target:
Áreas de investigación:
SYN1327 is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 can be used in studies related to IgG-mediated autoimmune diseases .
Referencia número: HY-P11786A
Target:
Áreas de investigación:
SYN1327 acetate is a potent monomeric cyclic competitive antagonistic peptide targeting the neonatal Fc receptor (FcRn), with a Kd of 31 nM for human FcRn at pH 6 and a Kd of 170 nM at pH 7.4. SYN1327 acetate competitively binds to the IgG-binding site of FcRn and inhibits the binding of human IgG to FcRn. SYN1327 acetate acts as the monomeric precursor of the dimeric peptide SYN1436 (HY-P11882). SYN1327 acetate can be used in studies related to IgG-mediated autoimmune diseases .
Referencia número: HY-P990951
No. CAS: 2845128-05-2
Synonyms: REGN-5381
Áreas de investigación:
Referencia número: HY-P991550
No. CAS: 505393-48-6
Referencia número: HY-P992142
No. CAS: 3050549-24-8
Synonyms: ANX-007
Target:
Áreas de investigación:
Referencia número: HY-159055
No. CAS: 3011682-49-5
Synonyms: ECC5004; AZD5004
Target:
Áreas de investigación:
Elecoglipron (AZD5004) is an orally active small-molecule GLP-1R agonist. Its IC50 against human GLP-1R is 2.4 nM. It activates the cAMP signaling pathway in HEK293 cells overexpressing human GLP-1R with a potency of 2.1 nM, and enhances glucose-stimulated insulin secretion in EndoC-βH5 cells with an EC50 of 5.9 nM, with no detectable β-arrestin-2 recruitment or GLP-1R internalization. Elecoglipron can be used in research related to obesity, overweight and type 2 diabetes .
Referencia número: HY-182014
No. CAS: 2408041-54-1
Target:
Áreas de investigación:
TLC-2716 is an orally available, gut- and liver-restricted inhibitor against LXRα and LXRβ, with EC50 values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .
Referencia número: HY-182502
No. CAS: 3092659-72-5
Target:
Áreas de investigación:
GLP-1R-agonist-43 (Compound A) is an orally active GLP-1R agonist with an EC50 of 2.68 nM. GLP-1R-agonist-43 can be used in the research of non-insulin-dependent diabetes mellitus (type 2 diabetes) and obesity .
Referencia número: HY-19870A
Synonyms: RM-493 TFA; BIM-22493 TFA; IRC-022493 TFA
Target:
Setmelanotide TFA (RM-493 TFA) is a blood-brain barrier-permeable, selective MC4R agonist with a Ki value of 2.1 nM for hMC4R. Setmelanotide TFA activates the CaMKK2/AMPK signaling pathway. Setmelanotide TFA mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide TFA is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .
Referencia número: HY-B0890
No. CAS: 64092-48-4
Synonyms: McN-2783-21-98
Target:
Áreas de investigación:
Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .
Referencia número: HY-B0890A
No. CAS: 33369-31-2
Synonyms: McN-2783-21-98 free acid
Target:
Áreas de investigación:
Zomepirac (McN-2783-21-98 free acid) is an orally active prostaglandin synthetase inhibitor. Zomepirac blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac can be used for the research of postoperative pain and osteoarthritis .
Referencia número: HY-B0890R
No. CAS: 64092-48-4
Synonyms: McN-2783-21-98 (Standard)
Target:
Áreas de investigación:
Zomepirac sodium salt (Standard) is the analytical standard of Zomepirac sodium salt (HY-B0890). This product is intended for research and analytical applications. Zomepirac sodium salt (McN-2783-21-98) is an orally active prostaglandin synthetase inhibitor. Zomepirac sodium salt blocks prostaglandin synthesis and inhibits Collagen (HY-P72147)- or Epinephrine (HY-B0447)-induced platelet aggregation. Zomepirac sodium salt can be used for the research of postoperative pain and osteoarthritis .
Referencia número: HY-P10031
Target:
Áreas de investigación:
Referencia número: HY-P10031A
Target:
Áreas de investigación:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
